Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
03:26pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
12:03pm, Wednesday, 23'rd Nov 2022
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos Corporation (GKOS) Q3 2022 Earnings Call Transcript
10:26pm, Friday, 04'th Nov 2022
Glaukos Corporation (NYSE:GKOS ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate Affairs Tom Burns - Chair
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
10:06am, Friday, 04'th Nov 2022 Benzinga
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Lincoln National Corporation (NYS
What 4 Analyst Ratings Have To Say About Glaukos
01:26pm, Thursday, 03'rd Nov 2022 Benzinga
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
12:48pm, Thursday, 03'rd Nov 2022
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
08:20pm, Wednesday, 02'nd Nov 2022
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
02:00pm, Monday, 31'st Oct 2022 Zacks Investment Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos
11:36am, Friday, 28'th Oct 2022 Zacks Investment Research
Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
12:51pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
10:33am, Thursday, 27'th Oct 2022
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock?
02:24pm, Friday, 14'th Oct 2022 Zacks Investment Research
Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
07:00am, Wednesday, 12'th Oct 2022
ALISO VIEJO, Calif.
